Kristen Marrone
Johns Hopkins University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kristen Marrone as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:37 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05472623 · Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without NivolumabSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · withdrawn · Resectable Non-Small Cell Lung Cancer · principal investigator
- Ph1NCT05254184 · KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLCSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · recruiting · Non-Small Cell Lung Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:37 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:37 UTC. The ranking covers the 200 most relevant of 9 PubMed records, and a shared surname and initials can bring in a namesake. All 9 on PubMed
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.N Engl J Med · 20181,689 citationsRCR 52.2
- Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.Lancet Oncol · 2020165 citationsRCR 6.3
- 122 citationsRCR 13.0
- 73 citationsRCR 2.6
- Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief Report.J Thorac Oncol · 202524 citationsRCR 4.3
- A pooled analysis of two phase II trials evaluating metformin plus platinum-based chemotherapy in advanced non-small cell lung cancer.Cancer Treat Res Commun · 201917 citationsRCR 0.7
- Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD.Ann Oncol · 202612 citationsRCR 6.0